Akers Biosciences, Inc. European Patent Granted (0622D)
January 26 2015 - 2:00AM
UK Regulatory
TIDMAKR
RNS Number : 0622D
Akers Biosciences, Inc.
26 January 2015
Embargoed: 0700hrs January 26, 2015
Akers Biosciences, Inc.
European Patent Granted for Akers' Rapid Blood Separation
Technology
Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the
"Company" or "Akers"), a leading designer and manufacturer of rapid
diagnostic screening and testing products, announces that the
European Patent Office has issued a patent surrounding the
Company's novel blood separator technology and method of separating
a fluid fraction from whole blood (the "Technology"). Akers was
granted U.S. patent protection for the Technology in 2011.
The Technology, developed and wholly owned by Akers, enables
rapid blood cell separation of small volumes of whole blood,
including those obtained from finger stick samples. By utilizing
the Technology, serum or plasma samples are extracted within 30-90
seconds and are ready for immediate analysis. By contrast,
conventional methods of blood cell separation are labor-intensive
and time consuming, taking 30-120 minutes, and typically involving
blood collection and laboratory personnel as well as
electrically-powered centrifuges and other specialized
equipment.
The Technology, which further accelerates the rate at which a
test result is obtained, is marketed by Akers under the brand name
seraSTAT(R) and forms a key component of the Company's PIFA product
range (Akers' proprietary platform for rapidly detecting or
measuring specific proteins or other substances through their
properties as antigens or antibodies). In addition to seraSTAT(R)'s
incorporation within some of the Company's own diagnostic tests,
Akers intends to license its proprietary blood separator Technology
to third parties seeking to accelerate their own testing procedures
by facilitating the blood cell separation process as a component of
their test.
"We believe the Company's blood separator Technology has a wide
range of potential applications and we are actively seeking
potential commercialization partners and licensees in both Europe
and the U.S.," said Raymond F. Akers, Jr. PhD, Co-founder and
Executive Chairman of the Board.
"This Technology can make blood cell separation dramatically
quicker and less resource-intensive than traditional methods - with
significant potential advantages related to cost savings, staff
efficiency, and the ability to perform certain diagnostic tests in
the field versus lab environments," continued Dr. Akers.
ABOUT AKERS BIOSCIENCES, INC.
Akers Biosciences develops, manufactures, and supplies rapid,
point of care screening and testing products designed to bring
healthcare information both rapidly and directly to the consumer or
healthcare provider. The Company has advanced the science of
diagnostics while responding to major shifts in healthcare through
the development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical products distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found on our website at www.akersbiosciences.com. Follow us on
Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
Raymond F. Akers, Jr. PhD
Executive Chairman of the Board
Tel. +1 856 848 8698
RedChip Companies, Inc. (US Investor Relations)
Jon Cunningham
Tel. +1 407 644 4256 x107
finnCap (UK Nominated Adviser and Broker)
Geoff Nash / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (UK Investor Relations)
Ben Simons / Alexandra Roper
Tel. +44 (0)20 7016 9570
Email. akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBJMPTMBMTBLA
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2023 to Apr 2024